[go: up one dir, main page]

BR112013018516A2 - constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantas - Google Patents

constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantas

Info

Publication number
BR112013018516A2
BR112013018516A2 BR112013018516-3A BR112013018516A BR112013018516A2 BR 112013018516 A2 BR112013018516 A2 BR 112013018516A2 BR 112013018516 A BR112013018516 A BR 112013018516A BR 112013018516 A2 BR112013018516 A2 BR 112013018516A2
Authority
BR
Brazil
Prior art keywords
nucleic acid
expression
alpha
plant cells
plants
Prior art date
Application number
BR112013018516-3A
Other languages
English (en)
Other versions
BR112013018516B1 (pt
Inventor
Shulman Avidor
Hanania Uri
Kizhner Tali
Shaaltiel Yoseph
Original Assignee
Protalix Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2011/000209 external-priority patent/WO2011107990A1/en
Application filed by Protalix Ltd. filed Critical Protalix Ltd.
Publication of BR112013018516A2 publication Critical patent/BR112013018516A2/pt
Publication of BR112013018516B1 publication Critical patent/BR112013018516B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

construto de ácido nucléico para expressão de alfa-galactosidase em plantas e células de plantas são apresentados construtos de expressão de ácido nucléicos e, mais especificamente, construtos de ácido nucléicos para expressão de alfa-galactosidase humana em células de planta, as plantas expressando o construto de ácido nucléico, produzindo a alfa-galactosidase humana, e seus usos.
BR112013018516-3A 2011-01-20 2011-09-07 Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição BR112013018516B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161434503P 2011-01-20 2011-01-20
US201161434499P 2011-01-20 2011-01-20
US61/434,499 2011-01-20
US61/434,503 2011-01-20
PCT/IL2011/000209 WO2011107990A1 (en) 2010-03-02 2011-03-02 Stabilized alpha-galactosidase and uses thereof
ILPCT/IL2011/000209 2011-03-02
PCT/IL2011/000719 WO2012098537A1 (en) 2011-01-20 2011-09-07 Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells

Publications (2)

Publication Number Publication Date
BR112013018516A2 true BR112013018516A2 (pt) 2019-05-21
BR112013018516B1 BR112013018516B1 (pt) 2023-11-07

Family

ID=44786043

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013018516-3A BR112013018516B1 (pt) 2011-01-20 2011-09-07 Construto de expressão de ácido nucleico, método de produção de uma proteína alfa-galactosidase humana recombinante, proteína alfagalactosidase humana, composição farmacêutica, e, uso de uma proteína alfagalactosidase humana ou de uma composição

Country Status (20)

Country Link
US (1) US9732333B2 (pt)
EP (2) EP3272861B1 (pt)
JP (1) JP5913372B2 (pt)
KR (1) KR101883803B1 (pt)
CN (1) CN103443270B (pt)
AU (1) AU2011356137A1 (pt)
BR (1) BR112013018516B1 (pt)
CA (1) CA2824791A1 (pt)
CY (1) CY1122794T1 (pt)
DK (2) DK2665814T3 (pt)
ES (1) ES2774190T3 (pt)
IL (1) IL227552B (pt)
LT (2) LT3272861T (pt)
LU (1) LUC00320I2 (pt)
PL (1) PL3272861T3 (pt)
PT (1) PT3272861T (pt)
RS (1) RS60129B1 (pt)
SI (1) SI3272861T1 (pt)
SM (1) SMT202000201T1 (pt)
WO (1) WO2012098537A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
SMT202000201T1 (it) 2011-01-20 2020-05-08 Protalix Ltd Composizioni di alfa-galattosidasi
CA2902727C (en) * 2013-03-06 2020-08-18 Protalix Ltd. Use of plant cells expressing a tnfalpha polypeptide inhibitor in therapy
WO2014136114A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
TW202332774A (zh) * 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
DK3271453T3 (da) 2015-03-17 2021-11-15 eleva GmbH Glycosylerede lysosomale proteiner, fremgangsmåde til fremstilling og anvendelser
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
KR20240042110A (ko) 2017-01-05 2024-04-01 프로탈릭스 리미티드 안정화된 알파-갈락토시다제를 이용하는 파브리의 치료를 위한 치료적 요법
IL257269A (en) * 2018-01-31 2018-04-09 Olender Tsviya Signaling is directed to the endoplasmic reticulum
KR102209198B1 (ko) * 2019-04-02 2021-02-02 주식회사 바이오앱 식물에서의 발현이 최적화된 재조합 이리신 유전자 및 이를 이용한 재조합 이리신 단백질의 생산 방법
KR102213745B1 (ko) 2019-04-16 2021-02-09 주식회사 바이오앱 돼지 유행성 설사병 바이러스 백신 조성물 및 이의 제조 방법
WO2020256372A1 (ko) 2019-06-17 2020-12-24 주식회사 바이오앱 아프리카 돼지열병의 진단을 위한 항원 생산용 재조합 벡터 및 이의 용도
US20240350614A1 (en) 2021-08-27 2024-10-24 Bioapplications Inc. Vaccine for preventing african swine fever, comprising african swine fever virus-derived antigen protein
KR102726138B1 (ko) 2023-10-17 2024-11-14 대한민국 백시니아 바이러스 재조합 a33r 단백질 및 이를 포함하는 오르소폭스바이러스 항체 진단 키트

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
CA1192510A (en) 1981-05-27 1985-08-27 Lawrence E. Pelcher Rna plant virus vector or portion thereof, a method of construction thereof, and a method of producing a gene derived product therefrom
JPS6054684A (ja) 1983-09-05 1985-03-29 Teijin Ltd 新規ｄνａ及びハイブリツドｄνａ
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
CA1288073C (en) 1985-03-07 1991-08-27 Paul G. Ahlquist Rna transformation vector
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
GB8608850D0 (en) 1986-04-11 1986-05-14 Diatech Ltd Packaging system
JPS6314693A (ja) 1986-07-04 1988-01-21 Sumitomo Chem Co Ltd 植物ウイルスｒｎａベクタ−
ATE108828T1 (de) 1987-02-09 1994-08-15 Lubrizol Genetics Inc Hybrides rns-virus.
US6846968B1 (en) 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5316931A (en) 1988-02-26 1994-05-31 Biosource Genetics Corp. Plant viral vectors having heterologous subgenomic promoters for systemic expression of foreign genes
US5693507A (en) 1988-09-26 1997-12-02 Auburn University Genetic engineering of plant chloroplasts
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5936035A (en) 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5302523A (en) 1989-06-21 1994-04-12 Zeneca Limited Transformation of plant cells
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
DE4009630C2 (de) 1990-03-26 1995-09-28 Reinhard Prof Dr Dr Brossmer CMP-aktivierte fluoreszierende Sialinsäuren sowie Verfahren zu ihrer Herstellung
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
UA48104C2 (uk) 1991-10-04 2002-08-15 Новартіс Аг Фрагмент днк, який містить послідовність,що кодує інсектицидний протеїн, оптимізовану для кукурудзи,фрагмент днк, який забезпечує направлену бажану для серцевини стебла експресію зв'язаного з нею структурного гена в рослині, фрагмент днк, який забезпечує специфічну для пилку експресію зв`язаного з нею структурного гена в рослині, рекомбінантна молекула днк, спосіб одержання оптимізованої для кукурудзи кодуючої послідовності інсектицидного протеїну, спосіб захисту рослин кукурудзи щонайменше від однієї комахи-шкідника
WO1993018148A2 (en) 1992-03-12 1993-09-16 Wisnieski Bernadine J Tumor necrosis factor with modified channel activity
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2144319A1 (en) 1993-07-09 1995-01-19 George N. Cox Recombinant ctla4 polypeptides and methods for making the same
US6329191B1 (en) 1993-08-30 2001-12-11 Hawaii Biotechnology Group, Inc. DNA encoding recombinant coffee bean alpha-galactosidase
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5994086A (en) 1994-03-30 1999-11-30 North Shore University Hospital Method for assessing infertility by binding of mannose to sperm cells
EP0807165A4 (en) 1995-01-30 1998-07-15 New York Blood Center Inc ENZYME -g (a) -GALACTOSIDASE RECOMBINANT
AU7071196A (en) 1995-09-14 1997-04-01 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
US6309646B1 (en) 1996-05-09 2001-10-30 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Protein-polysaccharide conjugate vaccines and other immunological reagents prepared using homobifunctional and heterobifunctional vinylsulfones, and processes for preparing the conjugates
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL119310A (en) 1996-09-26 1999-07-14 Metabogal Ltd Cell/tissue culturing device and method
US20010008766A1 (en) 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
IL125423A (en) 1998-07-20 2004-08-31 Israel State Alkaline alpha-galactosidase having broad substrate specificity
AU7645700A (en) 1999-10-07 2001-05-10 Maxygen Aps Single-chain antagonist polypeptides
US20070172449A1 (en) 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7244823B2 (en) 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
BR0116803A (pt) 2001-01-18 2004-02-17 Merck Patent Gmbh Proteìnas de fusão bifuncionais com atividade de glicocerebrosidase
PL369606A1 (en) 2001-10-22 2005-05-02 Applied Research Systems Ars Holding N.V. Gonadotrophins for folliculogenesis
EA007810B1 (ru) 2001-11-16 2007-02-27 Фармекса А/С Иммуногенные миметики мультимерных белков с нерегулярными вставками т-клеточных эпитопов
US20040071686A1 (en) 2002-04-25 2004-04-15 Treco Douglas A. Treatment of alpha-galactosidase A deficiency
CA2427190A1 (en) * 2002-04-30 2003-10-30 Alberta Research Council Inc. Production of recombinant epidermal growth factor in plants
WO2003097791A2 (en) 2002-05-15 2003-11-27 Agricultural Research Organization, The Volcani Center Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
EP1613264A4 (en) 2003-04-16 2007-08-15 Yeda Res & Dev MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US7951557B2 (en) * 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
GB2402677A (en) 2003-05-06 2004-12-15 Sirus Pharmaceuticals Ltd Biodegradable polymer
CN101027388A (zh) 2003-06-12 2007-08-29 建新公司 具有增强活性的修饰的人酸性神经磷脂酶及其制备方法
JP2005043317A (ja) 2003-07-25 2005-02-17 Olympus Corp 糖鎖と生体分子との反応を検出する方法
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20070275007A1 (en) 2003-11-05 2007-11-29 The Government Of The United States Of America, Represented By The Secretary Of Health And Human S Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer
WO2005056760A2 (en) 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated follicle stimulating hormone
AU2005211775B2 (en) 2004-02-06 2009-10-08 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2006093524A2 (en) 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
EP2441840B1 (en) 2005-07-18 2017-09-06 Protalix Ltd. Mucosal or enteral administration of biologically active macromolecules
KR20070065157A (ko) 2005-12-19 2007-06-22 이수근 고객맞춤형 투자자산 관리기능을 갖는 인터넷뱅킹 시스템및 방법
ES2569066T3 (es) 2006-07-25 2016-05-06 Lipoxen Technologies Limited Conjugación N-terminal de ácido polisiálico a proteínas
WO2008075957A1 (en) 2006-12-21 2008-06-26 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Treatment of fabry disease
PT2121713E (pt) 2007-01-18 2013-06-25 Genzyme Corp Oligossacáridos compreendendo um grupo aminooxi e seus conjugados
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
SG187447A1 (en) 2007-05-07 2013-02-28 Protalix Ltd Large scale disposable bioreactor
WO2008157263A2 (en) 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
US20110184293A1 (en) 2008-07-10 2011-07-28 Elisha Rabinovitz Device, method and kit for in vivo detection of a biomarker
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
WO2011107990A1 (en) * 2010-03-02 2011-09-09 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
EP2542572B1 (en) 2010-03-02 2015-05-06 Protalix Ltd. Multimeric forms of therapeutic proteins and uses thereof
SMT202000201T1 (it) 2011-01-20 2020-05-08 Protalix Ltd Composizioni di alfa-galattosidasi

Also Published As

Publication number Publication date
DK3272861T3 (da) 2020-03-23
WO2012098537A1 (en) 2012-07-26
EP2665814B1 (en) 2017-05-17
JP2014506450A (ja) 2014-03-17
CN103443270A (zh) 2013-12-11
PT3272861T (pt) 2020-03-26
US9732333B2 (en) 2017-08-15
SI3272861T1 (sl) 2020-06-30
LTPA2023531I1 (pt) 2023-11-27
CA2824791A1 (en) 2012-07-26
LUC00320I2 (pt) 2026-02-02
SMT202000201T1 (it) 2020-05-08
KR101883803B1 (ko) 2018-07-31
CN103443270B (zh) 2017-06-06
AU2011356137A1 (en) 2013-08-15
IL227552A0 (en) 2013-09-30
JP5913372B2 (ja) 2016-04-27
RS60129B1 (sr) 2020-05-29
WO2012098537A8 (en) 2013-08-08
DK2665814T3 (en) 2017-09-11
EP2665814A1 (en) 2013-11-27
BR112013018516B1 (pt) 2023-11-07
EP3272861B1 (en) 2019-12-18
CY1122794T1 (el) 2021-05-05
LT3272861T (lt) 2020-03-25
IL227552B (en) 2018-05-31
LTC3272861I2 (pt) 2025-09-10
KR20140015330A (ko) 2014-02-06
US20130295065A1 (en) 2013-11-07
EP3272861A1 (en) 2018-01-24
PL3272861T3 (pl) 2020-07-13
ES2774190T3 (es) 2020-07-17

Similar Documents

Publication Publication Date Title
BR112013018516A2 (pt) constructo de ácido nucléico para expressão de alfa-galactosidade em plantas e células de plantas
IL272324B (en) Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming
IL230212B (en) Media, compositions and methods for enhancing bioenergetic status in female germ cells
CL2016001065A1 (es) Locus genómicos óptimos de maíz para la inserción de genes exógenos y método para producir una célula vegetal transgénica.
BRPI1010010A2 (pt) Derivados de primidina-4-il-propanodinitrila, método para sua fabricação bem como seu uso como herbicidas e reguladores de crescimento de planta
BR112013033972A2 (pt) "constructos de dna recombinante, métodos para sua produção e para seus usos, planta e semente transgênicas, e método para produção de semente hibrida e semente hibrida assim produzida".
BR112015003149A2 (pt) células natural killer e usos das mesmas.
BR112014010455A2 (pt) Métodos para produzir um anticorpo, usos de il-e2 e/ou il-21, métodos para cultivar uma célula, usos de uma célula de mamífero e uso de sac no co- cultivo de células b
MY156847A (en) Solar cell and method of manufacture thereof, and solar cell module
MX2016002571A (es) Regulador de ph de transduccion.
LT2411028T (lt) Terapija, skirta skatinti ląstelių augimą
PL2661798T3 (pl) Sposób komunikacji, komunikacyjny system i zawierający go system magazynowania energii
BR112012018021A2 (pt) antídotos anticoagulantes.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
UY33974A (es) Molécula de adn que codifica elementos regulatorios de plantas, célula vegetal, planta y semilla transgénicas,métodos para obtenerlas y productos
BR112014006292A2 (pt) método para redução do coeficiente, método para produção de uma população de plantas, método para redução do número de plantas, construção e vetor de expressão recombinante, célula transgênica ou planta transgênica, uso de uma molécula e método para a produção de um produto agrícola
BR112013005855A2 (pt) heteroarilas fundidas e seus usos
PL2760282T3 (pl) Instalacja hodowli ryb, moduł, sposób i zastosowanie
CL2012002568A1 (es) Metodo para mejorar los rasgos relacionados con el rendimiento en plantas en relación con las plantas control que comprende modular la expresión en una planta de un acido nucleico que codifica un polipeptido tipo cle2; constructo que codifica polipeptido cle2; uso de dicho constructo para producir planta con mayor rendimiento , en particular mayor biomasa y/o mayor rendimiento de semillas.
EP2811023A4 (en) VECTOR SIMULTANEOUSLY EXPRESSING DODECAMER TRAIL AND SUICIDE HSV-TK GENES, AND ANTICANCER THERAPEUTIC AGENT BASED ON STEM CELLS USING THE SAME
CL2013001621A1 (es) Molecula de acido nucleico reguladora con especificidad definida, construccion de expresion que la comprende, vector; microorganismo, celula vegetal o animal; y metodo para la produccion de dicha molecula.
BRPI0922484A2 (pt) Cultura de célula de planta para produção de produtos naturais com contaminação de glucosinolato reduzida
UY34670A (es) Planta para la producción de peróxido de hidrógeno y proceso para su uso
BR112015017830A2 (pt) processos e meios para aumentar a tolerância ao estresse e a biomassa em plantas
CL2014002595A1 (es) Proceso de preparación de complejos vegetales activos y complejos vegetales/materias orgánicas dopados o sobre dopados, carbonatados, y sus aplicaciones en particular en metanización o fabricación de biogas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.6 NA RPI NO 2525 DE 28/05/2019 POR TER SIDO INDEVIDA. UMA VEZ QUE A 6A E A 7A ANUIDADE FORAM RECOLHIDAS CORRETAMENTE.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.2 NA RPI NO 2604 DE 01/12/2020 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/09/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.